drugset / Trial / NCT07031154
A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the major pathological response rate of Adibelimab combined with Apatinib neoadjuvant therapy in resectable non-small cell lung cancer.
Timeline
- Start
- 2025-06-30
- Primary completion
- 2027-02-01
- Completion
- 2027-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |